The Prognostic Value of the Merkel Cell Polyomavirus Serum Antibody Test: A Dual Institutional Observational Study
Testing Table 1
Now we are going to try @nte-table2
| Characteristic | N | Overall, N = 2611 | 95% CI2 | AMERK Status at Diagnosis | 95% CI2 | AMERK Status at Diagnosis | 95% CI2 |
|---|---|---|---|---|---|---|---|
| Seronegative, N = 1321 | Seropositive, N = 1291 | ||||||
| Sex | 261 | ||||||
| Male | 161 (62%) | 55%, 68% | 85 (64%) | 56%, 72% | 76 (59%) | 50%, 67% | |
| Female | 100 (38%) | 32%, 45% | 47 (36%) | 28%, 44% | 53 (41%) | 33%, 50% | |
| Age | 261 | 74 (67, 80) | 76 (70, 82) | 74, 78 | 71 (63, 78) | 68, 72 | |
| Immune Suppressed | 261 | 42 (16%) | 12%, 21% | 26 (20%) | 13%, 28% | 16 (12%) | 7.5%, 20% |
| Primary Site | 261 | ||||||
| Head/Neck | 97 (37%) | 31%, 43% | 69 (52%) | 43%, 61% | 28 (22%) | 15%, 30% | |
| Upper Extremity | 54 (21%) | 16%, 26% | 20 (15%) | 9.7%, 23% | 34 (26%) | 19%, 35% | |
| Occult Primary | 40 (15%) | 11%, 20% | 17 (13%) | 7.9%, 20% | 23 (18%) | 12%, 26% | |
| Lower Extremity | 35 (13%) | 9.6%, 18% | 10 (7.6%) | 3.9%, 14% | 25 (19%) | 13%, 27% | |
| Trunk | 24 (9.2%) | 6.1%, 14% | 15 (11%) | 6.7%, 18% | 9 (7.0%) | 3.4%, 13% | |
| Buttocks | 11 (4.2%) | 2.2%, 7.6% | 1 (0.8%) | 0.04%, 4.8% | 10 (7.8%) | 4.0%, 14% | |
| Clinical Stage | 261 | ||||||
| I | 108 (41%) | 35%, 48% | 64 (48%) | 40%, 57% | 44 (34%) | 26%, 43% | |
| II | 49 (19%) | 14%, 24% | 19 (14%) | 9.1%, 22% | 30 (23%) | 16%, 32% | |
| III | 89 (34%) | 28%, 40% | 42 (32%) | 24%, 41% | 47 (36%) | 28%, 45% | |
| IV | 14 (5.4%) | 3.1%, 9.0% | 6 (4.5%) | 1.9%, 10% | 8 (6.2%) | 2.9%, 12% | |
| Not Clinically Staged | 1 (0.4%) | 0.02%, 2.5% | 1 (0.8%) | 0.04%, 4.8% | 0 (0%) | 0.00%, 3.6% | |
| Pathological Stage | 261 | ||||||
| I | 46 (18%) | 13%, 23% | 27 (20%) | 14%, 29% | 19 (15%) | 9.3%, 22% | |
| IIA | 9 (3.4%) | 1.7%, 6.7% | 2 (1.5%) | 0.26%, 5.9% | 7 (5.4%) | 2.4%, 11% | |
| IIB | 3 (1.1%) | 0.30%, 3.6% | 2 (1.5%) | 0.26%, 5.9% | 1 (0.8%) | 0.04%, 4.9% | |
| IIIA | 72 (28%) | 22%, 34% | 32 (24%) | 17%, 33% | 40 (31%) | 23%, 40% | |
| IIIB | 31 (12%) | 8.3%, 17% | 14 (11%) | 6.1%, 17% | 17 (13%) | 8.1%, 21% | |
| IV | 6 (2.3%) | 0.94%, 5.2% | 3 (2.3%) | 0.59%, 7.0% | 3 (2.3%) | 0.60%, 7.2% | |
| Not Pathologically Staged | 94 (36%) | 30%, 42% | 52 (39%) | 31%, 48% | 42 (33%) | 25%, 41% | |
| Baseline ECOG | 261 | ||||||
| 0 | 145 (56%) | 49%, 62% | 66 (50%) | 42%, 58% | 79 (61%) | 52%, 70% | |
| 1 | 67 (26%) | 21%, 31% | 36 (27%) | 20%, 36% | 31 (24%) | 17%, 33% | |
| 2 | 31 (12%) | 8.3%, 17% | 18 (14%) | 8.5%, 21% | 13 (10%) | 5.7%, 17% | |
| 3 | 12 (4.6%) | 2.5%, 8.1% | 7 (5.3%) | 2.3%, 11% | 5 (3.9%) | 1.4%, 9.3% | |
| 4 | 1 (0.4%) | 0.02%, 2.5% | 1 (0.8%) | 0.04%, 4.8% | 0 (0%) | 0.00%, 3.6% | |
| Not Reported | 5 (1.9%) | 0.71%, 4.7% | 4 (3.0%) | 0.98%, 8.1% | 1 (0.8%) | 0.04%, 4.9% | |
| 1 n (%); Median (IQR) | |||||||
| 2 CI = Confidence Interval | |||||||
Table 1. Patient characteristics. Abbreviations: ECOG, Eastern cooperative oncology group.
Note
not working
Not sure what is going on